

***REMARKS******Amendment to Claim Eight***

Claim eight has been amended to remove a comma which was inadvertently inserted in the original application. This change is merely clerical, and no change to the substance or scope of claim eight is intended by Applicants.

***Restriction Requirement and Election***

The Office Action sets forth the following requirement for restriction:

- I. Claims 1–19, drawn to measuring the drug concentration attained in the blood stream to increase the extent of absorption of an oral dosage form of glycopyrrolate; measuring an increase of the maximum plasma concentration ( $C_{max}$ ) and the extent of absorption of glycopyrrolate at  $t = 24$  hours ( $AUC_{0-24\ hrs}$ ) under fasted conditions as compared to the administration of glycopyrrolate under fed conditions; increasing the oral bioavailability of glycopyrrolate, classified in class 436, sbuclass 111.
- II. Claims 20–27, drawn to methods for treating peptic ulcers or other gastrointestinal disorders and pharmaceutical compositions thereto in the form of a kit, classified in class 514, subclass 424.

Applicants elect, without traverse, the claims of Group I, directed to methods for increasing the oral bioavailability of glycopyrrolate, which includes pending claims 1–19. Claims 20–27 are canceled as being the subject matter of non-elected Group II. Applicants reserve the right to pursue the subject matter of claims 20–27 in a divisional application.

*Conclusion*

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



---

Steven H. Sklar, Reg. No. 42,154  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: August 30, 2005